Selenium and immunocompetence in patients with head and neck cancer

Biological Trace Element Research

Volumn 73, Issue 2, 2000, Pages 97-111

  Kiremidjian Schumacher, L ^a   Roy, M ^a   Glickman, R ^a   Schneider, K ^b   Rothstein, S ^b   Cooper, J ^b   Hochster, H ^b   Kim, M ^b   Newman, R ^c  

^a NEW YORK UNIVERSITY COLLEGE OF DENTISTRY   (United States)

^b NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^c HARLEM HOSPITAL CENTER   (United States)

Author keywords

Cell mediated; Immunity; Selenium; Squamous cell; Therapy

Indexed keywords

MITOGENIC AGENT; SELENIUM; SODIUM SELENITE;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOTOXICITY; DOUBLE BLIND PROCEDURE; FEMALE; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOCOMPETENCE; LYMPHOCYTE; MALE; MIXED LYMPHOCYTE REACTION; RANDOMIZED CONTROLLED TRIAL; SUPPLEMENTATION;

EID: 0034000404     PISSN: 01634984     EISSN: None     Source Type: Journal    
DOI: 10.1385/bter:73:2:97     Document Type: Article

References (44)

1. 1. Cancer Statistics 1999, CA: A Cancer J. Clinicians (January 1999).
2. 2. Cancer Facts and Figures for Minority Americans, 1991, American Cancer Society, Atlanta, GA, pp. 9-10 (1991).
3. 3. E. Y. Hilal, H. J. Wanebo, C. M. Pinsky, P. Middleman, E. W. Strong, and H. F. Oettgen, Immunologic evaluation and prognosis in patients with head and neck cancer, Am. J. Surg. 134, 469-473 (1977).
4. 4. M. J. Deegan, W. S. Coulthard, S. J. Qualman, and M. A. Shork, A correlative analysis of in vitro parameters of cellular immunity in patients with squamous cell carcinoma of the head and neck, Cancer Res. 37, 4475-4481 (1977).
5. 5. R. O. Gustafson, H. B. Neel III, and G. R. Pearson, Immunologic studies on cancer of the upper aerodigestive tract, Otolaryngol. Head Neck Surg. 90, 52-57 (1982).
6. 6. R. Roubin, F. Bekkoucha, and M. C. Fondaneche, Lymphoid cells in lymph nodes and peripheral blood of patients with squamous cell carcinoma of head and neck, J. Cancer Res. Clin. Oncol. 102, 277-287 (1982).
7. 7. T. Watanabe, J. D. Iglehart, and D. P. Bolognesi, Secretory immune response in patients with oropharyngeal carcinoma, Ann. Otol. Rhinol. Laryngol. 92, 295-299 (1983).
8. 8. P. L. Twomey, W. J. Catalona, and P. B. Chretien, Cellular immunity in cured cancer patients, Cancer 33, 435-440 (1974).
9. 9. J. Zighelboim, F. Dorey, V. H. Parker, J. Calceterra, P. Ward, and J. L. Fahey, Immunologic evaluation of patients with advanced head and neck cancer receiving weekly chemoimmunetherapy, Cancer 44, 117-123 (1979).
10. 10. D. P. Eskinazi, Y. Helman, A. G. Ershow, J. J. Perna, and R. Mihail, Nonspecific immunity and head and neck cancer: blastogenesis reviewed and revisited, Oral Surg. 60, 642-647 (1985).
11. 11. J. Lundy, H. Wanebo, C. Pinsky, E. Strong, and H. Oettgen, Delayed hypersensitivity reactions in patients with squamous cell cancer of the head and neck, Am. J. Surg. 128, 530-533 (1974).
12. 12. S. P. Schantz and H. G. Goepfert, Multimodality therapy and distant metastases: the impact of natural killer cell activity, Arch. Otolarngol. Head Neck Surg. 113, 1207-1213 (1987).
13. 13. S. P. Schantz and N. Ordonez, Quantitation of natural killer cell function and risk of metastatic poorly differentiated head and neck cancer, Natl. Immun. Cell Growth Regul. 10, 278-288 (1991).
14. 14. S. P. Schantz, B. W. Brown, E. Lira, D. L. Taylor, and N. Beddingfield, Evidence for the role of natural immunity in the control of metastatic spread of head and neck cancer, Cancer Immunol. Immunother. 25, 141-148 (1987).
15. 15. C. A. Perez, Effects of irradiation and chemotherapy in the immune response and potential investigations in patients with head and neck cancer, Laryngoscope 88, 1-9 (1978).
16. 16. Z. L. Orlowski and S. A. Wilkins, T-lymphocyte levels in the peripheral blood of patients with cancer of the head and neck, Am. J. Surg. 130, 440-444 (1975).
17. 17. R. E. Pollock, E. Lotzova, and S. D. Stanford, Surgical stress impaires natural killer cell programming of tumor lysis in patients with sarcomas in other solid tumors, Cancer 70, 2192-2202 (1992).
18. 18. M. Roy, L. Kiremidjian-Schumacher, H. I. Wish, M. W. Cohen, and G. Stotzky, Supplementation with selenium and human immune cell functions. I. Effect on lymphocyte proliferation and interleukin 2 receptor expression, Biol. Trace Element Res. 41, 103-114 (1994).
19. 19. L. Kiremidjian-Schumacher, M. Roy, H. I. Wish, M. W. Cohen, and G. Stotzky, Supplementation with selenium and human immune cell functions. II. Effect on cytotoxic lymphocyes and natural killer cells, Biol. Trace Element Res. 41, 115-127 (1994).
20. 20. C. B. Begg and B. Iglewicz, A treatment allocation procedure for sequential clinical trials, Biometrics 36, 81-90 (1980).
21. 21. Committee on Dietary Allowances, Food and Nutrition Board, National Research Council, Recommended Dietary Allowances, 9th ed., National Academy Press, Washington, DC, 1980.
22. 22. M. Janghorbani, R. F. Martin, L. J. Kasper, X. F. Sun, and V. R. Young, The selenite-exchangeable metabolic pool in humans: a new concept for the assessment of selenium status, Am. J. Clin. Nutr. 51, 670-677 (1990).
23. 23. M. Roy, L. Kiremidjian-Schumacher, H. I. Wish, M. W. Cohen, and G. Stotzky, Supplementation with selenium and immune cell function II. Effects on lymphocyte-mediated cytotoxicit, Proc. Soc. Exp. Biol. Med. 193, 143-148 (1990).
24. 24. B. E. Jacobson and G. Lockitch, Direct determination of selenium in serum by graphite furnace atomic absorption spectrometry with deuterium background correction and a reduced palladium modifier: age specific reference ranges, Clin. Chem. 34, 15-30 (1988).
25. 25. H. J. Wanebo, D. Blackinton, and N. Kouttab, Contribution of serum inhibitory factors and immune cellular defects to depressed cell-mediated in patients with head and neck cancer, Am. J. Surg. 166, 389-394 (1993).
26. 26. H. E. Katz, Update on immunology of head and neck cancer, Med. Clin. North Am. 77, 625-631 (1993).
27. 27. B. Phillips, M. E. Marshall, S. Brown, and J. S. Thompson, Effect of smoking on human natural killer cell activity, Cancer 56, 2789-2792 (1985).
28. 28. G. J. Hauser, M. M. Chan, and W. F. Casey, Immune dysfunction in children after corrective surgery for congenital heart disease, Crit. Care Med. 19, 874-881 (1991).
29. 29. M. S. Slade, R. L. Simmons, and E. Yunis, Immunodepression after major surgery in normal patients, Surgery 78, 363-372 (1975).
30. 30. J. L. Tarpley, C. Potvin, and P. B. Chretien, Prolonged depression of cellular immunity in cured laryngopharyngeal cancer patients treated with radiation therapy, Cancer 35, 638.
31. 31. M. Roy, L. Kiremidjian-Schumacher, H. I. Wishe, M. W. Cohen, and G. Stotzky, Effect of selenium on the expression of high affinity interleukin-2 receptors, Proc. Soc. Exp. Biol. Med. 200, 36-46 (1992).
32. 32. M. Roy, L. Kiremidjian-Schumacher, H. I. Wishe, M. W. Cohen, and G. Stotzky, Effect of selenium supplementation on the IL2 receptor subunit expression and IL2 internalization, Proc. Exp. Biol. Med. 202, 295-301 (1993).
33. 33. L. Kiremidjian-Schumacher, M. Roy, H. I. Wishe, M. W. Cohen, and G. Stotzky, Regulation of cellular immune responses by selenium, Biol. Trace Element Res. 33, 23-35 (1992).
34. 34. W. J. Goodwin, H. W. Lane, K. Bradford, M. V. Marshall, C. Griffin, H. Geopfert, et al., Selenium and glutathione peroxidase levels in patients with epidermoid carcinoma of the oral cavity and oropharynx, Cancer 51, 110-115 (1983).
35. 35. W. L. Broghamer, Jr., K. P. McConnell, and A. L. Blotcky, Relationship between serum selenium levels and patients with carcinoma, Cancer 37, 1384-1388 (1976).
36. 36. L. Kiremidjian-Schumacher and G. Stotzky, Selenium and immune responses. A review, Environ. Res. 42, 277-303 (1987).
37. 37. W. C. Willet, B. V. Polk, J. S., Morris, M. J. Stampler, S. Pressie, B. Rosner, et al., Prediagnostic serum selenium and risk of cancer, Lancet 2, 130-134 (1983).
38. 38. G. N. Schrauzer, D. A. White, and C. J. Schneider, Cancer mortality correlation studies IV: Associations with dietary intakes and blood levels of certain trace elements, notably Se-antagonists, Bioinorg. Chem. 7, 35-56 (1977).
39. 39. G. F. Combs, Selenium and cancer prevention, in Antioxidants and Disease Prevention, H. Garewal, ed., CRC Press, Boca Raton, FL, pp. 97-105 (1997).
40. 40. P. R. Harrison, J. Lanfear, L. Wu, J. Fleming, L. McGarry, and L. Blower, Chemopreventive and growth inhibitory effects of selenium, Biomed. Environ. Sci. 10, 235-245 (1997).
41. 41. G. N. Schrauzer, Selenium. Mechanistic aspects of anticarcinogenic action, Biol. Trace Element Res. 33, 51-62 (1992).
42. 42. F. R. Khuri, S. M. Lippman, M. R. Spitz, and R. Lotan, Molecular epidemiology and retinoid chemoprevention of head and neck cancer, J. Natl. Cancer Inst. 89, 199-211 (1997).
43. 43. L. C. Clark, G. F. Combs, B. W. Turmbull, E. H. Slate, D. Alberts, D. Abele, et al., Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin, J. Am. Med. Assoc. 276, 1957-1963 (1996).
44. 44. G. F. Combs, L. C. Clark, and B. W. Turnbull, Reduction of cancer risk with oral supplement of selenium, Biomed. Environ. Sci. 10, 227-234 (1997).